Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All

Patient Enrollment Begins in Phase 3 Blepharitis Study

November 17, 2011 11:52 am | News | Comments

InSite Vision announced that patient enrollment has begun in the Phase 3 clinical trial of AzaSite Plus and DexaSite for the treatment of blepharitis.

Prosensa Receives Two Exon-Skipping Patents

November 17, 2011 10:54 am | News | Comments

Prosensa has been granted two patents for exon-skipping by the Japanese Patent Office and the U.S. Patent and Trademark Office.


Scientists Identify Antimalarial Class of Compounds

November 17, 2011 10:50 am | News | Comments

Scientists from the Genomics Institute of the Novartis Research Foundation and The Scripps Research Institute discovered a family of chemical compounds that could lead to a generation of anti-malarial drugs capable of alleviating symptoms and preventing the disease.


Borosilicate Centrifuge Tubes

November 17, 2011 7:08 am | Drug Discovery & Development | Product Releases | Comments

Kimble Chase disposable centrifuge tubes are made from borosilicate glass in compliance with ASTM Specification E438, Type I, Class A or B, and capable of withstanding a relative centrifugal force of 2,980.


PCR Recovery Device

November 17, 2011 7:00 am | Product Releases | Comments

G-Biosciences' G-Capsule is a electro-elution device for rapid recovery of PCR products, DNA fragments, and proteins from agarose and polyacrylamide gels. The G-Capsule method eliminates additional steps that involve washing, spinning, heating or precipitation.


GPU Applications Accelerate Search for Medicines

November 17, 2011 6:50 am | News | Comments

NVIDIA announced that four applications for material-science and biomolecular modeling—LAMMPS, GROMACS, GAMESS, and QMCPACK—have added support for multiple GPU acceleration, enabling them to cut simulation times from days to hours.

Safety Analysis Shows No Increased Dapagliflozin Risk

November 17, 2011 6:44 am | News | Comments

Results from a meta-analysis of cardiovascular safety data from 14 Phase 2b/3 trials in adult patients with type 2 diabetes showed that dapagliflozin was not associated with an unacceptable increase in cardiovascular risk.


New TB Treatment Limits Infection And Drug Resistance

November 17, 2011 6:24 am | News | Comments

A team of researchers has shown that Mycobacterium tuberculosis and several of its close relatives exploit a family of host enzymes known as ABL-family tyrosine kinases to gain entry into host cells and to survive once inside.


FDA Panel Backs Expanded Prevnar Usage

November 17, 2011 6:19 am | News | Comments

A panel of federal health experts voted overwhelmingly to recommend that Pfizer's best-selling vaccine be approved for a new use in preventing pneumococcal disease in adults age 50 and older.


New Drug Combo Targets Multiple Cancers

November 17, 2011 6:14 am | News | Comments

Researchers say a novel combination of a specific sugar molecule with a pair of cell-killing drugs prompts a wide variety of cancer cell types to kill themselves, a process called apoptosis or programmed cell death.


EU Approves Vyndaqel

November 17, 2011 6:05 am | News | Comments

Pfizer Inc. said that European Union regulators approved its drug Vyndaqel as a treatment for transthyretin familial amyloid polyneuropathy, a potentially fatal genetic condition.


J & J Pressured to Remove Potential Carcinogens

November 17, 2011 6:01 am | News | Comments

Amid pressure from activists, Johnson & Johnson said that it is continuing efforts to remove traces of two harmful chemicals from its baby products around the world.


Personalized Medicine Advances, But Faces Challenges

November 16, 2011 11:43 am | News | Comments

In its latest report, The Case for Personalized Medicine, the Personalized Medicine Coalition documents the growth of commercially available personalized medicine products from 13 in 2006 to 72 currently.

Genzyme Reports on Phase 2 Mipomersen Trial

November 16, 2011 11:34 am | News | Comments

Genzyme presented positive results from a Phase 2 trial to evaluate the effect of weekly injections of mipomersen on low-density lipoprotein cholesterol in high-risk patients intolerant to statins.

Boehringer Ingelheim Invests $350 Million in Facilities

November 16, 2011 11:26 am | News | Comments

In 2011,, Boehringer Ingelheim made more than $350 million in capital investments throughout its U.S. operations  expanding  drug discovery, development and manufacturing capabilities.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.